Literature DB >> 10711857

Once-daily inhaled corticosteroids in children with asthma: dry powder inhalers.

C Möller1.   

Abstract

The cornerstone of pharmacological management of asthma in childhood is inhaled corticosteroids. These drugs are intended for long term treatment and, consequently, compliance is a major issue. Once-daily administration of maintenance medication would simplify treatment and it is likely that it would lead to better compliance. Moreover, the excellent safety profile of inhaled corticosteroid treatment tailored to disease severity may, theoretically, be further improved with once-daily administration. Studies comparing inhaled corticosteroids given once or twice daily to patients with asthma indicate that unstable asthma is best treated with at least 2 daily doses. On the other hand, it has been demonstrated that, if the asthma is stabilised, most children can be treated with inhaled corticosteroids once daily without loss of efficacy. Thus, the data suggest that newly diagnosed asthma, or asthma after deterioration, should first be reliably controlled with inhaled corticosteroids divided into at least 2 daily doses. Once-daily maintenance treatment should then be tried with the aim of improving compliance and quality of life. A dry powder inhalation device is probably the best choice for children from the age of 5 years.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10711857     DOI: 10.2165/00003495-199958004-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  56 in total

1.  Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma.

Authors:  Y Nakamura; M Hoshino; J J Sim; K Ishii; K Hosaka; T Sakamoto
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

2.  Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids.

Authors:  G Jónasson; K H Carlsen; P Blomqvist
Journal:  Eur Respir J       Date:  1998-11       Impact factor: 16.671

3.  Lung deposition of budesonide from turbuhaler in asthmatic children.

Authors:  J H Wildhaber; S G Devadason; J M Wilson; C Roller; T Lagana; L Borgström; P N LeSouëf
Journal:  Eur J Pediatr       Date:  1998-12       Impact factor: 3.183

4.  Duration of action of inhaled terbutaline at two different doses and of albuterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in asthmatic subjects.

Authors:  J L Malo; H Ghezzo; C Trudeau; A Cartier; J Morris
Journal:  Am Rev Respir Dis       Date:  1989-09

5.  How often is medication taken as prescribed? A novel assessment technique.

Authors:  J A Cramer; R H Mattson; M L Prevey; R D Scheyer; V L Ouellette
Journal:  JAMA       Date:  1989-06-09       Impact factor: 56.272

6.  Efficacy of once-daily versus twice-daily administration of budesonide by Turbuhaler(R) in children with stable asthma.

Authors:  C Möller; L Strömberg; G Oldaeus; E Arweström; M Kjellman
Journal:  Pediatr Pulmonol       Date:  1999-11

7.  Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

Authors:  L Agertoft; S Pedersen
Journal:  Respir Med       Date:  1994-05       Impact factor: 3.415

8.  Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide.

Authors:  J H Toogood; J C Baskerville; B Jennings; N M Lefcoe; S A Johansson
Journal:  J Allergy Clin Immunol       Date:  1982-10       Impact factor: 10.793

9.  Depending on the time of administration, dexamethasone potentiates or blocks growth hormone-releasing hormone-induced growth hormone release in man.

Authors:  F F Casanueva; B Burguera; M A Tome; L Lima; J A Tresguerres; J Devesa; C Dieguez
Journal:  Neuroendocrinology       Date:  1988-01       Impact factor: 4.914

10.  Dose frequency in the treatment of asthmatics with inhaled topical steroids. Comparison between a twice daily and a once daily dosing regimen.

Authors:  E P Munch; L C Laursen; A Dirksen; E R Weeke; B Weeke
Journal:  Eur J Respir Dis       Date:  1985-10
View more
  2 in total

Review 1.  Rationale for once-daily therapy in asthma: compliance issues.

Authors:  M E Hyland
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders.

Authors:  K M Hvizdos; B Jarvis
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.